Edition:
United States

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.97USD
22 Jul 2016
Change (% chg)

$0.30 (+8.17%)
Prev Close
$3.67
Open
$3.71
Day's High
$4.00
Day's Low
$3.70
Volume
49,221
Avg. Vol
28,639
52-wk High
$4.35
52-wk Low
$1.25

NYMX.OQ

Chart for NYMX.OQ

About

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging... (more)
No analyst recommendations are available for NYMX.OQ.

Overall

Beta: 0.74
Market Cap(Mil.): $177.81
Shares Outstanding(Mil.): 44.79
Dividend: --
Yield (%): --

Financials

  NYMX.OQ Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -0.58 -- --
ROI: -- -5.86 14.35
ROE: -- -4.70 15.56

BRIEF-Nymox Pharmaceutical reports results of prostate cancer study

* Nymox reports long-term prostate cancer results in 7 year prospective study of 995 u.s. Middle-Aged and elderly men without cancer

Jun 22 2016

Competitors

  Price Chg
Siemens AG (SIEGn.DE) €94.82 -0.30
Johnson & Johnson (JNJ.N) $125.03 -0.12
Pfizer Inc. (PFE.N) $36.74 +0.03
Novartis AG (NOVN.S) CHF82.35 +0.40
Merck & Co., Inc. (MRK.N) $58.82 +0.03
Roche Holding Ltd. (ROG.S) CHF249.80 -0.20
Roche Holding Ltd. (RO.S) CHF252.25 +0.50
Abbott Laboratories (ABT.N) $43.17 +0.13
AstraZeneca plc (AZN.L) 4,612.50p +89.00
Eli Lilly and Co (LLY.N) $81.59 +1.19

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.